JPWO2020074010A5 - - Google Patents

Info

Publication number

JPWO2020074010A5

JPWO2020074010A5 JP2021520113A JP2021520113A JPWO2020074010A5 JP WO2020074010 A5 JPWO2020074010 A5 JP WO2020074010A5 JP 2021520113 A JP2021520113 A JP 2021520113A JP 2021520113 A JP2021520113 A JP 2021520113A JP WO2020074010 A5 JPWO2020074010 A5 JP WO2020074010A5

Authority

JP

Japan

Prior art keywords

solvate

pharmaceutically acceptable

acceptable salt

pharmaceutical composition

administered

Prior art date

2022-10-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 18
• 150000003839 salts Chemical class 0.000 claims 18
• 239000012453 solvate Substances 0.000 claims 18
• 150000001875 compounds Chemical class 0.000 claims 11
• 229930012538 Paclitaxel Natural products 0.000 claims 10
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 10
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 10
• 229960005277 gemcitabine Drugs 0.000 claims 10
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 10
• 229960001592 paclitaxel Drugs 0.000 claims 10
• 201000002528 pancreatic cancer Diseases 0.000 claims 10
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 10
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 10
• 238000001802 infusion Methods 0.000 claims 8
• 230000003442 weekly effect Effects 0.000 claims 8
• 206010028980 Neoplasm Diseases 0.000 claims 4
• 201000011510 cancer Diseases 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 238000002560 therapeutic procedure Methods 0.000 claims 4
• 238000009104 chemotherapy regimen Methods 0.000 claims 3
• 210000004027 cell Anatomy 0.000 claims 2
• 238000002512 chemotherapy Methods 0.000 claims 2
• 238000009096 combination chemotherapy Methods 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 2
• 230000001394 metastastic effect Effects 0.000 claims 2
• 206010061289 metastatic neoplasm Diseases 0.000 claims 2
• 230000035755 proliferation Effects 0.000 claims 2
• 238000009097 single-agent therapy Methods 0.000 claims 2
• 210000000130 stem cell Anatomy 0.000 claims 2
• 230000004083 survival effect Effects 0.000 claims 2
• 238000009121 systemic therapy Methods 0.000 claims 2
• 229940028652 abraxane Drugs 0.000 claims 1
• 230000000973 chemotherapeutic effect Effects 0.000 claims 1
• 238000011254 conventional chemotherapy Methods 0.000 claims 1
• 238000009093 first-line therapy Methods 0.000 claims 1
• PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 claims 1
• 238000009472 formulation Methods 0.000 claims 1
• 239000007972 injectable composition Substances 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 230000000306 recurrent effect Effects 0.000 claims 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
• 238000009094 second-line therapy Methods 0.000 claims 1
• 230000009885 systemic effect Effects 0.000 claims 1
• 238000002626 targeted therapy Methods 0.000 claims 1
• 238000009095 third-line therapy Methods 0.000 claims 1